Granupas (Aminosalicylic Acid)

Granupas may be prescribed for the management of certain bacterial infections and inflammatory conditions as determined by a qualified clinician.

• Treatment of Mycobacterium tuberculosis infections in combination therapy
• Adjunct therapy for ulcerative colitis or other inflammatory bowel diseases
• Management of chronic bacterial infections resistant to standard agents
• Use in clinical trials investigating anti‑inflammatory mechanisms
• Supportive therapy in selected cases of sarcoidosis or other granulomatous disorders

Side effects of aminosalicylic acid can vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

• Nausea, abdominal discomfort, or loss of appetite
• Mild headache or dizziness
• Skin rash or mild itching
• Elevated liver enzymes without symptoms
• Transient discoloration of urine

Serious

• Severe allergic reaction with swelling of face or throat
• Hepatotoxicity presenting as jaundice or dark urine
• Blood dyscrasias such as agranulocytosis or thrombocytopenia
• Persistent fever or unexplained weight loss
• Renal impairment indicated by reduced urine output

Before starting Granupas, certain health considerations should be reviewed with a healthcare provider.

• Assess liver and kidney function, especially in patients with pre‑existing disease
• Discuss pregnancy, lactation, or plans for conception, as safety data are limited
• Review any history of hypersensitivity to salicylates or related compounds
• Monitor blood counts regularly during prolonged therapy
• Evaluate for concurrent use of other immunosuppressive agents
• Ensure proper hydration to reduce risk of renal side effects

Aminosalicylic acid can interact with several medications, requiring careful management.

Avoid

• Concurrent use with sulfonamide antibiotics due to additive toxicity
• Combination with anticoagulants such as warfarin, which may increase bleeding risk
• Co‑administration with high‑dose methotrexate, potentially enhancing toxicity
• Use with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may exacerbate gastrointestinal irritation

Use with caution

• Oral contraceptives, as efficacy may be reduced
• Antidiabetic agents, monitoring for altered glucose control
• Lithium therapy, observing for signs of lithium toxicity
• Immunosuppressants, requiring closer laboratory monitoring